Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio's Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization.
The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio's method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development.
Mursla Bio's Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company's lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³.
Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature's native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.'
Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology.
For further information on Mursla Bio's AI Precision Medicine Platform, please visit https://mursla.com/ai-precision-platform/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial. Share In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital. About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
Business Wire
an hour ago
- Business Wire
CoStar Group Names Alexa-Maria Rathbone Barker as Head of CoStar for Europe
LONDON--(BUSINESS WIRE)--CoStar Group (NASDAQ: CSGP), a global leader in commercial real estate information, analytics, online marketplaces and 3D digital twin technology, today announced the appointment of Alexa-Maria Rathbone Barker as Head of CoStar Europe. This leadership elevation comes as part of the company's strategic growth plan across Europe. In her expanded role, Alexa will oversee CoStar's operations in the UK, reaffirming the company's position as the most trusted provider of real-time, verified commercial real estate (CRE) intelligence. Her responsibilities will include deepening CoStar's relationships with key players in the CRE space - especially among agencies - and helping clients grow through collaboration and partnerships. Beyond her UK remit, Alexa will also lead CoStar's European expansion. With product launches planned in France, Spain, and Germany, her multilingual skills and pan-European expertise will be instrumental in driving growth and building CoStar's footprint in new markets. Alexa joined CoStar Group as Head of European Sales, where over the past three years she led sales strategy and execution for the company's market-leading platforms across the UK and Europe. Prior to that, she spent a decade at Bloomberg, holding senior leadership positions focused on international growth and heading the European Analytics team. Fluent in English, French, and Spanish, Alexa brings a rare combination of extensive product knowledge, insight, regional expertise, and cross-cultural fluency to her new position. 'Alexa's extensive experience, deep knowledge of the CRE landscape, and her clear understanding of our clients' evolving needs make her the ideal choice to lead CoStar's efforts across the UK and Europe,' said Robin Rossmann, Managing Director, Europe at CoStar Group. 'Her promotion is a testament to our ongoing commitment to cultivating talent and delivering world-class services to our clients.' About CoStar Group, Inc. CoStar Group (NASDAQ: CSGP) is a global leader in commercial real estate information, analytics, online marketplaces and 3D digital twin technology. Founded in 1986, CoStar Group is dedicated to digitizing the world's real estate, empowering all people to discover properties, insights, and connections that improve their businesses and lives. CoStar Group's major brands include CoStar, a leading global provider of commercial real estate data, analytics, and news; LoopNet, the most trafficked commercial real estate marketplace; the leading platform for apartment rentals; and the fastest-growing residential real estate marketplace. CoStar Group's industry-leading brands also include Matterport, a leading spatial data company whose platform turns buildings into data to make every space more valuable and accessible, STR, a global leader in hospitality data and benchmarking, Ten-X, an online platform for commercial real estate auctions and negotiated bids and OnTheMarket, a leading residential property portal in the United Kingdom. CoStar Group's websites attracted over 130 million average monthly unique visitors in the first quarter of 2025, serving clients around the world. Headquartered in Arlington, Virginia, CoStar Group is committed to transforming the real estate industry through innovative technology and comprehensive market intelligence. From time to time, we plan to utilize our corporate website as a channel of distribution for material company information. For more information, visit
Business Insider
an hour ago
- Business Insider
Everyone is saying AI will reshape banking. A new report forecasts exactly how much.
A new report attempts to put hard numbers on a question hanging over every Wall Street corner office: just how much of banking work will AI actually change? Artificial intelligence is on track to redefine 44% of the work done at banks by 2030, according to ThoughtLinks, an independent consulting firm. ThoughtLinks — which is led by founder and CEO Sumeet Chabria, a former tech and operations COO at Bank of America and a Wall Street veteran — mapped nearly 5,000 individual banking "processes" to see which roles or units at banks will experience the most upheaval in their roles. ThoughtLinks found that tech, engineering, and infrastructure—collectively considered one sector — would be most susceptible to transformation, with a projection of 55% of the work involved in that sector being redefined by 2030. It's a logical outcome, considering how many of the tasks in these fields are precisely the kinds that automation is best suited to handle. Front office, client-facing sectors are hardly immune. Commercial banking could be redefined by as much as 49% by 2030, wealth management to the tune of 42%, and investment banking by as much as 33%, according to the report. Wall Street banks are investing heavily to compete. JPMorgan has deployed a large language model suite to its 200,000 employees, while Goldman Sachs has rolled out its own ChatGPT-like sidekick, GS AI Assistant. Citigroup also last week announced a new leadership team to drive AI strategy for its nearly quarter-million workers worldwide. It's important to note that these numbers do not reflect ThoughtLinks' predictions about how many jobs could be lost or created as a result of AI — rather, they look at how much of the work done by those who work in banks could be done differently thanks to the implementation of artificial intelligence. To assess how much each banking process could be redefined, ThoughtLinks developed a framework that maps what bank employees do to nearly 5,000 individual "processes." "'Redefined' reflects substantial AI-enabled, process-level change via automation, resequencing, elimination, or redesign," the firm wrote in its report. In an interview, Chabria said that breaking finance jobs down to their most basic components would be critical to understanding how to retrain workers in the face of the AI revolution. "Clearly, you've got to keep the level of agility," he said, "because things are going to change." Chabria shared three examples with Business Insider of how he anticipates sectors to respond to AI-driven changes. We got a look at snapshots for commercial banking, investment banking, and wealth management. Take a look at what's already transforming, what will be adapted by 2030, and the parts of the job that may stay mostly in the hands of humans for now. Commercial banking: 49% redefined by 2030 What's already being automated: First-generation banking advisor copilot services are now live, helping bankers obtain insights on clients, quickly summarize notes or files, draft basic memos, or flag policy exceptions. Some manual workflows — like creating spreadsheets, drafting emails, and navigating legacy systems — are being replaced. This reduces time doing manual work, as well as human error. Customers have access to virtual AI-enabled assistants on corporate banking systems that give them personalized insights and enable them to do routine transactions more quickly. What is expected to be redefined by 2030: Client onboarding: GenAI will help guide client onboarding conversations and tailor explanations, while the next iteration of AI will likely be able to verify forms and assess risks. Banks will leverage AI to assess small business creditworthiness to expand credit access. Banks will use AI to adjust loan pricing, fee structures, and product terms based on clients' behavior, financial patterns, and market conditions. AI tools will help detect some breaches and generate internal alerts in real time, increasing security 24/7. What is likely to resist being redefined by AI: Large corporate lending will still require human credit judgment and board oversight. Banks will need to rely on legal, tax, risk, and structuring teams. Investment Banking: 33% redefined by 2030 What's already being automated: Drafting documents like prospectuses or pitchbooks is being digitized. Generative AI tools can now pull in some market data, past deals, financial comps, and company-branded slides to build draft pitchbooks in minutes. Internal AI copilots are accelerating deal prep. Bankers can now use GPT-based tools to instantly summarize earnings calls, analyst reports, and client financials. Generative AI tools can now review documents, flag missing disclosures, and summarize new regulatory changes. What is expected to be redefined by 2030: Banks will leverage AI to simulate investor demand or model pricing scenarios for equity and debt offerings. (Final allocation will remain human-led.) AI will help bankers test thousands of ways to structure a deal by adjusting debt, equity, pricing, and covenants to find the right balance for clients. What is likely to resist being redefined by AI: Final IPO and syndicate pricing will remain human-led. Setting the price for a new issuance will require banker judgment, market feel, and live investor feedback. Winning mandates and advising the C-suite will remain relationship-driven and led by humans, who will use AI to enhance their knowledge or judgment and land new mandates. Wealth Management: 42% redefined by 2030 What's already being automated: AI copilots can now answer questions, generate meeting prep docs, and summarize client portfolios — in seconds. Financial planning is faster and becoming more scalable. Tools powered by generative AI can aid advisors in building personalized plans that simulate life events, goals, and risk tolerance without starting from scratch. Client reporting is now becoming personalized with custom commentary on investment performance, market moves, and risk tailored to each client's portfolio. What is expected to be redefined by 2030: Tax management will become more automated and timely. AI will help tailor advice and investment strategies to reflect individual preferences, financial behavior, and goals. On the flip side, clients may use AI to manage their wealth in their own portfolio with smart triggers. What is likely to resist being redefined by AI: Client engagement and coaching will remain human. During market downturns or personal events, clients still want empathy, reassurance, and value judgment that only a trusted advisor can provide.
